Comparing a new drug to standard chemo for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has spread or cannot be surgically removed.
- You have already tried platinum-based chemotherapy and an immunotherapy drug (PD-1 or PD-L1 inhibitor), and it no longer works.
- You are at least 18 years old and expected to live at least 3 more months.
- You have at least one tumor that can be measured on scans.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have not received certain prior treatments like specific antibody-drug conjugates or both paclitaxel and docetaxel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.